Skip to main content
Clinical Trials/NCT04597320
NCT04597320
Completed
Phase 4

The Effects of Esketamine Sedation Compared With Fentanyl Sedation in Pediatric Dental Patients: A Double Blind, Randomized Controlled Trial

Peking University1 site in 1 country48 target enrollmentStarted: January 1, 2022Last updated:

Overview

Phase
Phase 4
Status
Completed
Sponsor
Peking University
Enrollment
48
Locations
1
Primary Endpoint
Midazolam use

Overview

Brief Summary

Since the 1970s, ketamine has been used in clinical anesthesia treatment. Compared with ketamine, esketamine has a higher clearance rate, so it has a shorter recovery time after anesthesia. This feature also makes ketamine more suitable for pediatric dental patients.The purpose of this study was to investigate and compare the efficacy of esketamine sedation and fentanyl sedation in pediatric dental patients

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
6 Years to 14 Years (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age 6-14 years old.
  • Oral out-patient sedative treatment in our hospital.
  • BMI between 18 to 30 kg/m
  • ④. ASA: I-II degree. ⑤. Sign the informed consent.

Exclusion Criteria

  • Patients who are allergic to esketamine, opioids, propofol, or have contraindications for these drug use.
  • Patients with mental illness or who are unable to cooperate.
  • Patients who have abnormal reaction to midazolam. ④. Patients who suffer from Apnea. ⑤. Patients who refuse to sign informed consent. ⑥. Patients who participated in other clinical trials within 4 weeks.

Arms & Interventions

Fentanyl group

Active Comparator

The fentanyl group was prepared by 1ug/kg fentanyl in 5ml normal saline, assembled with 5ml injection, labeled as "Anesthesia inducer". Midazolam 0.05mg/kg+ "Anesthesia inducer" was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg.

Intervention: Fentanyl (Drug)

Fentanyl group

Active Comparator

The fentanyl group was prepared by 1ug/kg fentanyl in 5ml normal saline, assembled with 5ml injection, labeled as "Anesthesia inducer". Midazolam 0.05mg/kg+ "Anesthesia inducer" was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg.

Intervention: Midazolam (Drug)

Esketamine group

Experimental

The esketamine group was prepared by 0.5mg/kg esketamine in 5ml normal saline, assembled with 5ml injection, labeled as "Anesthesia inducer". Midazolam 0.05mg/kg+ "Anesthesia inducer" was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg.

Intervention: Esketamine (Drug)

Esketamine group

Experimental

The esketamine group was prepared by 0.5mg/kg esketamine in 5ml normal saline, assembled with 5ml injection, labeled as "Anesthesia inducer". Midazolam 0.05mg/kg+ "Anesthesia inducer" was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg.

Intervention: Midazolam (Drug)

Outcomes

Primary Outcomes

Midazolam use

Time Frame: Day 0

The total use of midazolam

Hypoxemia

Time Frame: Day 0

The incidence of intraoperative hypoxemia (Spo2\<92%)

Secondary Outcomes

  • Successful sedation(Day 0)
  • Agitation and delirium(Day 0)
  • Propofol requiring(Day 0)
  • Recall of intraoperative events(Day 0)
  • Respiratory depression(Day 0)
  • The time for Modified Observer Assessment of Sedation Score(MOAA/S)>4(Day 0)
  • Directional force recovery time(Day 0)
  • Circulatory fluctuation(Day 0)
  • Time of successful sedation(Day 0)
  • MOAA/S score in recovery room(Day 0)
  • Treatment comfort score(Day 0)
  • The incidence of complications(Day 1)
  • Visual Analogue Scale(VAS) of pain in recovery room(Day 0)

Investigators

Sponsor
Peking University
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Yang Xudong

Chief of Department of Anesthesiology

Peking University

Study Sites (1)

Loading locations...

Similar Trials